Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab treatment extension study in multiple myeloma
CTR20231956Phase 2Active
- Sponsor
- Sanofi
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Aug 2023; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20231956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231956.